U.S. Controlled Substance Market (Product Type: Opioids, Stimulants, Depressants, and Cannabinoids) - - Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The U.S. Controlled Substance market size was exhibited at USD 47.32 billion in 2022 and is projected to hit around USD 80.07 billion by 2032, growing at a CAGR of 5.4% during the forecast period 2023 to 2032.

Controlled substances are basically controlled drugs or prescribed medications, which are designated by the law and their production & use are regulated by the government. These controlled substances or controlled prescribed medications are used in treatment of several types of neurological disorders as well as in drug research. Various product types of controlled substances are, opioids, stimulants, depressants, and cannabinoids drugs.

The U.S. controlled substance market is likely to grow at a steady pace during the forecast period, owing to the increasing demand for controlled substances as drugs on chronic pain.

U.S. Controlled Substance Market Report Scope

High Incidence Rate of Chronic Pain among Geriatric Population to Drive Demand for Controlled Substances in U.S.

Chronic pain persists for a longer duration, and the number of patients suffering from chronic pain is increasing. According to data provided by the Centers for Disease Control and Prevention, in 2022, an estimated 21.9% adults in the U.S. had chronic pain, and 8.6% adults had high-impact chronic pain.

Moreover, increase in geriatric population that is more prone to chronic pain, due to reduced mobility and lack of activity, is projected to propel to demand for controlled substance. The WHO stated that the growth rate of the geriatric population would be higher in developed countries, especially in countries such as the U.S. According to the U.S. Census Bureau, around 89 million people are expected to be aged over 65 years in the U.S. by 2050.

Introduction of New Controlled Substance Products to Boost Market in U.S.

The launch of new products is estimated to boost the market, as this would provide more options for effective treatment. Controlled drugs for depression, or other drugs such as amphetamine, which are available in the market in different forms can be easily abused, primarily by adolescents. Several pharmaceutical companies are taking interest or initiatives to introduce some new products or capsule control drugs in the market in order to provide better treatment to people suffering from chronic diseases. For instance, in 2020, Trevena, Inc., a biopharmaceutical company, received the U.S. FDA approval for its brand OLINVYK (oliceridine) injection for the management of acute pain in adults. In addition, the FDA recently approved cocaine-based products, such as C-Topical in topical form, to provide anesthetic support during procedures.

Opioid Segment to Lead U.S. Controlled Substance Market

Opioid is basically used to treat moderate to severe pain. The growth of the opioid segment can be attributed to the consistent rise in population that suffers from pain, and an opioid is used as a component in the management of pain. Awareness about the advantages of these drugs to treat different types of pain and availability through different distribution channels, such as online mode prescribed by specialists, have increased considerably. Therefore, a rise in the demand for opioids for use in pain management is one of the major reasons that boosts the market.

In terms of revenue, the opioid product type segment accounted for a dominant share of the market in 2022. The segment is anticipated to expand at a high CAGR rate from 2023 to 2032.

Need for Pain Management to Drive Demand for Controlled Drugs

The pain management segment is projected to account for a notable share of the global market. Pain can lead to severe complications if proper care or treatment is not provided for a longer time. Unattained pain results in many health issues such as vein thrombosis, reduced patient mobility, and pulmonary embolism. Therefore, doctors usually prescribe analgesics in the initial stage of pain. If the patient remains unresponsive for the initial medications then, these controlled drugs are used for further treatment. Thus, this increase in use of controlled drugs is estimated to fuel the demand for controlled substances.

Geriatric individuals and people suffering from chronic pain caused by cancer and other diseases can be effectively treated with controlled substance drugs; hence, an increase in usage of controlled substances is estimated to propel the market significantly during the forecast period.

Retail Pharmacies to Remain Preferred Distribution Channel for Drug Sales

Based on distribution channel, the U.S. controlled substance market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounted for a dominant market share of the market, in terms of revenue, in 2022. The segment is anticipated to grow at a high CAGR during the forecast period.

Medicines for various neurological disorders, pain management, etc., are prescribed for a long period, which prompts patients to prefer retail stores instead of visiting hospitals. A rise in the number of retail pharmacies, owing to the growth of international pharmacy corporates in the U.S., and initiatives taken by key players in strengthening their distribution networks are also expected to boost the segment.

Some of the prominent players in the U.S. Controlled Substance Market include:

• AbbVie, Inc.
• Pfizer, Inc.
• Merck & Co., Inc
• Mallinckrodt plc
• F. Hoffmann-La Roche AG
• Janssen Pharmaceuticals, Inc.
• Purdue Pharma L.P.
• Teva Pharmaceutical Industries Ltd.
• Other Prominent Players

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. Controlled Substance market.

Product Type

• Opioids
• Stimulants
• Depressants
• Cannabinoids Drugs

Indication

• Pain Management
• Sleep Disorder
• Anxiety
• Seizure
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies